Saturday, October 31, 2026

Virgin Galactic Stock Bullish Momentum With A 29% Rise In The Last 21 Sessions

ViaNews Editorial Team

February 3, 2023

Virgin Galactic Stock Bullish Momentum With A 29% Rise In The Last 21 Sessions

(VIANEWS) - Shares of Virgin Galactic (NYSE: SPCE) rose by a staggering 29.63% in 21 sessions from $4.89 to $6.34 at 11:09 EST on Friday, after five successive sessions in a row of gains. NYSE is dropping 0.55% to $16,033.98, after three consecutive sessions in a row of gains.

Virgin Galactic's last close was $6.34, 76.08% under its 52-week high of $26.50.

About Virgin Galactic

Virgin Galactic Holdings, Inc. focuses on the development, manufacture, and operation of spaceships and related technologies for conducting commercial human spaceflight and flying commercial research and development payloads into space. It is also involved in the ground and flight testing, and post-flight maintenance of its spaceflight system vehicles. The company serves private individuals, researchers, and government agencies. Virgin Galactic Holdings, Inc. was founded in 2017 is headquartered in Las Cruces, New Mexico. Virgin Galactic Holdings, Inc. was a former subsidiary of Virgin Orbit Holdings, Inc.

Earnings Per Share

As for profitability, Virgin Galactic has a trailing twelve months EPS of $-1.55.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -53.97%.

Sales Growth

Virgin Galactic's sales growth is negative 89.5% for the present quarter and negative 48.1% for the next.

Growth Estimates Quarters

The company's growth estimates for the current quarter is 12.8% and a drop 12.5% for the next.

Yearly Top and Bottom Value

Virgin Galactic's stock is valued at $6.34 at 11:09 EST, way below its 52-week high of $26.50 and way above its 52-week low of $4.76.

More news about Virgin Galactic (SPCE).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com